Almost two-thirds of the children who died with H1N1 had epilepsy, cerebral palsy or other neurodevelopmental conditions.
About one in 13 H1N1 deaths in the United States have been children, and most of them have been of school age, according to the Centers For Disease Control and Prevention.
More than 40 U.S. children have died from the virus since it was first identified in here in April.
The CDC has found some differences in the pediatric death toll from H1N1 as compared with seasonal flu, including:
• Normally, half or more of the children who die from flu are age 4 and younger. More than 80% of the children with H1N1 were age 5 or older.
• Almost two-thirds of the children who died with H1N1 had epilepsy, cerebral palsy or other neurodevelopmental conditions. In a previous flu season, only one-third of pediatric deaths had those conditions.
• Bacterial co-infections were a big danger and were blamed in most of the deaths of otherwise healthy children.
The general consensus is that there are two main issues: getting information about the virus to high-risk populations; and addressing those who may be sick as well as the “worried well.”
“Such an effort must be undertaken in a way that is supportive but does not cause alarm,” says Alexandra Drane, president and co-founder of Eliza Corp., who recently attended a summit on H1N1 preparedness in Washington, D.C.
“Despite all the attention we’ve spent on preparing for potential H1N1 outbreaks, we must all stay vigilant in our efforts to prevent seasonal flu, especially among populations who may not be as vulnerable to the H1N1 virus,” Drane tells Managed Healthcare Executive.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
A Motor Neuron Mystery Points to New Potential SMA Treatment Targets
December 20th 2024Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has discovered that even in muscles that appeared resistant to SMA, subtle changes had occurred at the cellular level.
Read More